| Title: |
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial |
| Authors: |
Noor, N. M.; Lee, J. C.; Bond, S.; Dowling, F.; Brezina, B.; Patel, K. V.; Ahmad, T.; Banim, P. J.; Berrill, J. W.; Cooney, R.; De La Revilla Negro, J.; de Silva, S.; Din, S.; Durai, D.; Gordon, J. N.; Irving, P. M.; Johnson, M.; Kent, A. J.; Kok, K. B.; Moran, G. W.; Mowat, C.; Patel, P.; Probert, C. S.; Raine, T.; Saich, R.; Seward, A.; Sharpstone, D.; Smith, M. A.; Subramanian, S.; Upponi, S. S.; Wiles, A.; Williams, H. R. T.; van den Brink, G. R.; Vermeire, S.; Jairath, V.; D'Haens, G. R.; McKinney, E. F.; Lyons, P. A.; Lindsay, J. O.; Kennedy, N. A.; Smith, K. G. C.; Parkes, M. |
| Publisher Information: |
Elsevier |
| Publication Year: |
2024 |
| Collection: |
RD&E Research Repository (Royal Devon and Exeter NHS Foundation Trust) |
| Description: |
BACKGROUND: Management strategies and clinical outcomes vary substantially in patients newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic biomarker to guide therapy by assessing outcomes in patients randomised to either top-down (ie, early combined immunosuppression with infliximab and immunomodulator) or accelerated step-up (conventional) treatment strategies. METHODS: PROFILE (PRedicting Outcomes For Crohn's disease using a moLecular biomarker) was a multicentre, open-label, biomarker-stratified, randomised controlled trial that enrolled adults with newly diagnosed active Crohn's disease (Harvey-Bradshaw Index =7, either elevated C-reactive protein or faecal calprotectin or both, and endoscopic evidence of active inflammation). Potential participants had blood drawn to be tested for a prognostic biomarker derived from T-cell transcriptional signatures (PredictSURE-IBD assay). Following testing, patients were randomly assigned, via a secure online platform, to top-down or accelerated step-up treatment stratified by biomarker subgroup (IBDhi or IBDlo), endoscopic inflammation (mild, moderate, or severe), and extent (colonic or other). Blinding to biomarker status was maintained throughout the trial. The primary endpoint was sustained steroid-free and surgery-free remission to week 48. Remission was defined by a composite of symptoms and inflammatory markers at all visits. Flare required active symptoms (HBI =5) plus raised inflammatory markers (CRP >upper limit of normal or faecal calprotectin =200 µg/g, or both), while remission was the converse-ie, quiescent symptoms (HBI |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://linkinghub.elsevier.com/retrieve/pii/S2468-1253(24)00034-7; The lancet. Gastroenterology & hepatology; https://hdl.handle.net/11287/623219 |
| DOI: |
10.1016/s2468-1253(24)00034-7 |
| Availability: |
https://hdl.handle.net/11287/623219; https://doi.org/10.1016/s2468-1253(24)00034-7 |
| Rights: |
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd. All rights reserved. |
| Accession Number: |
edsbas.A0A71F87 |
| Database: |
BASE |